Evaluation of a commercial ELISA as alternative to plaque reduction neutralization test to detect neutralizing antibodies against SARS-CoV-2

High-throughput detection of neutralizing antibodies against SARS-CoV-2 presents a valuable tool for vaccine trials or investigations of population immunity. We evaluate the performance of the first commercial surrogate virus neutralization test (sVNT, GenScript Biotech) against SARS-CoV-2 plaque re...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofmann, Natalie, Grossegesse, Marica, Neumann, Markus, Schaade, Lars, Nitsche, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894493/
https://www.ncbi.nlm.nih.gov/pubmed/35241780
http://dx.doi.org/10.1038/s41598-022-07597-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894493/
https://www.ncbi.nlm.nih.gov/pubmed/35241780
http://dx.doi.org/10.1038/s41598-022-07597-3

Ejemplares similares